Company news
Siga Technologies Inc. (NASDAQ:SIGA) news
Every Siga Technologies Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
October 27, 2022
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
October 12, 2022
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
September 29, 2022
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
September 26, 2022
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
August 9, 2022
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
August 4, 2022
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
July 28, 2022
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
July 15, 2022
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
July 12, 2022
SIGA Technologies Receives Approval from UK for Tecovirimat
July 8, 2022
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
June 23, 2022
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
June 22, 2022
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
May 19, 2022
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
May 12, 2022
SIGA Reports Financial Results for Three Months Ended March 31, 2022
May 5, 2022
SIGA Declares Special Dividend of $0.45 Per Share
May 5, 2022
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
April 28, 2022
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
March 3, 2022
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
March 2, 2022
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
January 25, 2022
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 18, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
January 10, 2022
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
December 1, 2021
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
November 16, 2021
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
November 4, 2021
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
October 28, 2021
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
September 13, 2021
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
September 7, 2021
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
August 5, 2021
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
July 29, 2021
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
July 29, 2021
SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom
June 30, 2021
SIGA Reports Financial Results for Three Months Ended March 31, 2021
May 6, 2021
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
May 4, 2021
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
April 29, 2021
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
March 23, 2021
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020
March 4, 2021
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
February 26, 2021
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®
January 13, 2021
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
November 12, 2020
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020
November 5, 2020
SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results
October 29, 2020
SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX®
October 8, 2020
SIGA to Participate at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020
September 10, 2020
Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research
August 31, 2020
SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020
August 6, 2020
SIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results
July 30, 2020
SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications
July 30, 2020
SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million
June 25, 2020